OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
FAIL · Does not pass the screen
2.87 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price2.87 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-04Read Markup2.50+14.6% to today ✓Distribution gives way to Markup after an 11% rise in 7 days
2026-10-28Read Distribution2.25+27.3% to today Markdown gives way to Distribution after a 46% slide in 12 weeks
2026-08-07Read Markdown4.20-31.8% to today ✓Distribution gives way to Markdown
2026-07-02Read Distribution4.20-31.8% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
OnKure Therapeutics Inc holds its Markup at $2.87. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$2.87
Valuation
N/A trailing · -1.97 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.88%
Below 33%
Interest-bearing debt is just 0.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
95.06%
Below 49%
Money owed to the company is 95.1% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
OnKure Therapeutics's business is fine, but its receivables are about 95% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OKUR's ethical verdict changes
Today OKUR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OKUR trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup · changed$2.50+11.1%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-10-28Distribution · changed$2.25+0.0%Entry 8
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-10-21Markdown$2.25-26.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 26.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-10-02Markdown$3.06-27.1%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 27.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 32% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-09-08Markdown$4.20+0.0%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 32% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-08-07Markdown · changed$4.20+0.0%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 32% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-07-18Distribution$4.20+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 32% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 40%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (5 analysts) rates it none, with a mean price target of $20.
2026-07-03Distribution$4.20+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$4.20Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.